Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:

• Introduction (0:00)
• Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24)
• Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10)
• Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54)
• Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00)
• Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33)
• Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05)
• FL and Other NHL Subtypes — Dr Sehn (45:30)

CME information and select publications

Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics:

• Introduction (0:00)
• Best of ASH Multiple Myeloma (1:56)
• Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35)
• Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58)
• Case: A man in his mid 80s with severe obesity and coronary artery disease, chronic heart failure and sleep apnea receives belantamab mafodotin with low-dose pomalidomide for multiregimen-relapsed myeloma — Neil Morganstein, MD (27:57)
• Case: A man in his mid 60s with a history of stroke with aphasia receives teclistamab for multiregimen-relapsed MM after daratumumab, proteasome inhibitors, immunomodulatory drugs and selinexor — Justin Favaro, MD, PhD (34:42)
• Integrating Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies into the Management of R/R MM — Dr Mateos (39:09)
• Case: A man in his early 70s with kappa light chain myeloma experiences complete response on cilta-cel CAR T-cell therapy with hypogammaglobulinemia requiring IVIG and develops melanoma of the abdominal wall — Bhavana (Tina) Bhatnagar, DO (52:07)
• Case: A man in his mid 50s with heavily relapsed MM who received multiple prior lines of therapy, including CAR T-cell therapy, receives talquetamab — Priya Rudolph, MD, PhD (55:44)

CME information and select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O'Shaughnessy, including the following topics:

• Introduction (0:00)
• Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck (1:39)
• Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer — Alan B Astrow, MD (12:52)
• Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues due to neuropathy — Laila Agrawal, MD (20:02)
• Previously Untreated HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (25:10)
• Case: A woman in her early 80s presents with de novo metastatic (bone-only) ER-positive, HER2-positive breast cancer — Zanetta S Lamar, MD (35:03)
• Optimal Management of Brain Metastases in Patients with HER2-Positive Breast Cancer — Dr Lin (46:20)
• Case: A woman in her early 60s with ER-positive, HER2-positive breast cancer develops a cerebellar metastasis while receiving adjuvant anastrozole after prior anti-HER2 therapy — Justin Favaro, MD, PhD (59:41)
• Case: A woman in her early 40s with ER-negative, HER2-positive mBC develops a headache shortly after neoadjuvant TCHP, surgery and postneoadjuvant T-DM1 and is found to have an isolated 4-cm brain metastasis — Dr Agrawal (1:05:36)
• Selection and Sequencing of Therapy for Relapsed/Refractory HER2-Positive mBC in the Absence of CNS Involvement — Dr Krop (1:12:00)
• Case: A woman in her early 40s with ER-positive, HER2-positive mBC receives THP (docetaxel/trastuzumab/pertuzumab) and maintenance tucatinib with trastuzumab/pertuzumab on a clinical trial and now has disease progression — Yanjun Ma, MD, PhD (1:23:04)
• Tolerability Considerations with HER2-Targeted Therapies — Dr O'Shaughnessy (1:29:32)
• Case: A woman in her mid 60s presents with localized ER-negative, HER2-positive infiltrating ductal carcinoma — Erik Rupard, MD (1:46:06)
• Case: A woman in her early 70s with recurrent ER-positive, HER2-positive mBC receives trastuzumab deruxtecan (T-DXd) and has concerning pulmonary symptoms but without findings on diagnostic imaging — Kimberly Ku, MD
  Case: A woman in her mid 40s with ER-positive, HER2-positive breast cancer metastatic to the brain and lung who received multiple prior treatments responds to T-DXd but develops Grade 1 interstitial lung disease — Richard Zelkowitz, MD (1:49:49)

CME information and select publications